Abstract
Background. Diagnoses of genital warts (GW) in genitourinary medicine (GUM) clinics have been increasing in England for many years. In 2008, an HPV immunization program began with a bivalent vaccine (Cervarix). This was expected to markedly reduce infections and disease due to human papillomavirus (HPV) 16/18 but not HPV 6/11 infections or disease. However, from 2009 to 2011 there were decreases in reported diagnoses of GW in young females at GUM clinics.Methods. Using data from GUM clinics and a sample of general practices (GPs) throughout England, we analyzed rates of GW diagnoses by age, year of diagnosis, and estimated immunization coverage.Results. The overall reduction in GW diagnoses at GUM clinics between 2008 and 2011 was 13.3% among 16- to 19-year-old females, with the greatest decline of 20.8% in 17-year-olds. Declines were positively associated with estimated immunization coverage. A similar pattern was seen in GP diagnoses, but not among older women, and for other GUM consultations.Conclusions. Several factors might contribute to declines in GW. However, the size and pattern of the declines strongly suggest that we are observing an unexpected, moderately protective effect of HPV 16/18 vaccination against GW.
| Original language | English |
|---|---|
| Pages (from-to) | 1397-1403 |
| Number of pages | 7 |
| Journal | Journal of Infectious Diseases |
| Volume | 208 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1 Nov 2013 |
Bibliographical note
Funding Information:Financial support. CPRD is funded by the Medicines and Healthcare products Regulatory Agency (MHRA) and the NHS National Institute for Health Research (NIHR). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in writing the manuscript; or in the decision to submit the paper for publication.
Keywords
- Cervarix
- HPV immunization
- genital warts
- surveillance
